Buckle Up AbbVie, Amgen: Biohaven’s Oral CGRP Drug is Gaining Traction in Migraine, Doctors’ Survey Shows

From: FiercePharma

By: Angus Liu

 

With recent FDA approvals, the race for supremacy in migraine treatment is heating up among oral CGRP inhibitors, and a doctors’ survey is offering an early look at the winners.

Piper Sandler conducted the survey with Spherix Global Insights a few weeks ahead of Qulipta’s FDA go-ahead in late September. When asked to project each drug’s prevention share by first-quarter 2022, physicians reported only a small disruption for Nurtec if Qulipta reaches the market, putting Biohaven med’s at a 17% share without the AbbVie option or 16% in the case of the competitive launch…(read more)